The SURMOUNT-MAINTAIN trial found that continuing tirzepatide at the maximum tolerated dose effectively maintains bodyweight reduction in adults with obesity, while a lower 5 mg dose offers a potential alternative to stopping treatment entirely. Results from the phase 3 PHOENYCS GO trial showed that dapirolizumab pegol, a CD40 ligand inhibitor, produced significant improvements in disease activity among patients with systemic lupus erythematosus.
Obesity requires ongoing management to preserve weight loss and associated cardiometabolic benefits, yet many patients struggle with long-term adherence. The trial underscores that tirzepatide's effectiveness hinges on continued therapy, though individual responses may vary. For SLE, an autoimmune disease with highly variable symptoms and flare patterns, a new targeted therapy could address an unmet need.
In the SURMOUNT-MAINTAIN trial, researchers did not disclose specific numerical outcomes for weight maintenance or the exact patient numbers in each arm. The PHOENYCS GO study likewise reported significant improvement without precise data on response rates or adverse events in this release. Both trials were randomized, double-blind, and placebo-controlled, lending rigor to the findings.
These results support a shift toward individualized, patient-centered obesity care, where dose adjustments could improve tolerance while keeping benefits. For the approximately 200,000 Americans living with SLE, dapirolizumab pegol may represent a novel treatment pathway if confirmed in further trials. Regulatory and commercial timelines remain unclear.
Experts caution that without detailed numerical data, the magnitude of benefit is hard to assess, and longer-term safety data for dapirolizumab pegol are still pending.